Cyclo Therapeutics, Inc. (CYTH) Income Statement Analysis

See more : PXP Energy Corporation (PXPEF) Income Statement Analysis – Financial Results

Complete financial analysis of Cyclo Therapeutics, Inc. (CYTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyclo Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Cyclo Therapeutics, Inc. (CYTH)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.cyclotherapeutics.com

About Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Revenue	1.08M	1.38M	1.59M	903.38K	1.01M	1.01M	1.24M	1.50M	950.46K	1.57M	1.69M	1.04M	1.03M	802.37K	623.87K	494.94K	751.18K	542.31K	454.36K	464.69K	394.53K	522.37K	289.43K	384.59K
Cost of Revenue	98.46K	138.93K	156.08K	66.40K	75.49K	105.03K	132.92K	198.43K	124.43K	272.64K	426.02K	139.68K	273.76K	114.66K	110.83K	99.32K	118.40K	125.19K	66.66K	78.83K	45.43K	84.48K	34.03K	99.22K
Gross Profit	977.95K	1.24M	1.43M	836.98K	931.71K	906.45K	1.10M	1.30M	826.03K	1.29M	1.27M	905.27K	758.09K	687.71K	513.04K	395.62K	632.77K	417.13K	387.70K	385.87K	349.10K	437.89K	255.40K	285.37K
Gross Profit Ratio	90.85%	89.90%	90.16%	92.65%	92.50%	89.62%	89.26%	86.80%	86.91%	82.61%	74.84%	86.63%	73.47%	85.71%	82.24%	79.93%	84.24%	76.92%	85.33%	83.04%	88.48%	83.83%	88.24%	74.20%
Research & Development	14.18M	9.00M	9.15M	6.10M	4.87M	2.71M	2.29M	1.86M	658.51K	94.13K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	5.66M	7.81M	6.50M	3.68M	3.43M	2.43M	2.62M	2.64M	2.22M	1.53M	639.54K	560.17K	799.60K	678.64K	693.33K	520.06K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	3.90K	13.06K	18.34K	5.01K	5.89K	5.64K	7.85K	7.16K	7.57K	10.90K	8.91K	10.81K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	6.83M	7.82M	6.52M	3.68M	3.44M	2.44M	2.63M	2.65M	2.23M	1.55M	648.45K	570.98K	799.60K	678.64K	693.33K	520.06K	439.10K	350.68K	500.32K	664.78K	263.50K	240.54K	279.11K	548.79K
Other Expenses	0.00	30.50K	27.54K	19.95K	13.98K	13.95K	19.77K	130.95K	202.02K	217.52K	188.76K	159.93K	32.75K	20.94K	20.65K	22.87K	439.10K	350.68K	500.32K	664.78K	263.50K	240.54K	279.11K	575.21K
Operating Expenses	21.04M	16.85M	15.70M	9.80M	8.32M	5.16M	4.95M	4.65M	3.09M	1.86M	837.21K	730.91K	832.35K	699.58K	713.98K	542.93K	439.10K	350.68K	500.32K	664.78K	263.50K	240.54K	279.11K	575.21K
Cost & Expenses	21.13M	16.99M	15.85M	9.86M	8.40M	5.27M	5.08M	4.85M	3.22M	2.13M	1.26M	870.59K	1.11M	814.24K	824.81K	642.25K	557.51K	475.86K	566.97K	743.61K	308.93K	325.02K	313.14K	674.43K
Interest Income	0.00	12.47K	3.41K	19.80K	12.03K	0.00	0.00	0.00	0.00	0.00	0.00	3.51K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00		0.00	0.00	0.00	0.00	0.00	28.60K	31.29K	33.67K	53.87K	61.80K	25.81K	4.31K	0.00	1.82K	10.75K	11.05K	13.96K	12.03K	22.60K	30.92K	35.44K	28.29K
Depreciation & Amortization	19.28K	19.48K	16.83K	12.76K	5.68K	10.12K	9.27K	107.10K	169.03K	152.45K	148.04K	142.64K	32.75K	20.94K	20.58K	22.87K	24.37K	27.46K	35.01K	27.76K	37.82K	24.19K	51.29K	26.41K
EBITDA	-20.03M	-15.60M	-14.27M	-8.95M	-7.39M	-4.24M	-3.82M	-4.09M	-2.23M	-406.57K	486.82K	303.65K	-39.21K	12.72K	-172.55K	-188.55K	218.04K	-63.32K	-77.60K	-251.15K	90.92K	221.54K	27.58K	-66.02K
EBITDA Ratio	-1,860.90%	-1,145.03%	-897.54%	-992.49%	-719.16%	-419.60%	-309.54%	-215.26%	-220.57%	-26.15%	34.14%	30.34%	-4.02%	1.13%	-28.91%	-25.14%	26.28%	46.31%	-56.50%	4.17%	29.51%	42.57%	8.63%	-69.09%
Operating Income	-20.05M	-15.61M	-14.27M	-8.96M	-7.39M	-4.27M	-3.84M	-4.21M	-2.41M	-562.31K	336.65K	157.49K	-74.26K	-11.87K	-200.94K	-239.47K	193.67K	-45.90K	-112.61K	-278.91K	85.60K	197.35K	-23.71K	-289.84K
Operating Income Ratio	-1,862.69%	-1,134.76%	-899.77%	-991.85%	-733.80%	-421.84%	-310.51%	-279.85%	-253.22%	-35.87%	19.88%	15.07%	-7.20%	-1.48%	-32.21%	-48.38%	25.78%	-8.46%	-24.78%	-60.02%	21.70%	37.78%	-8.19%	-75.36%
Total Other Income/Expenses	-7.25K	171.00K	3.41K	19.80K	12.03K	11.77K	10.26K	-17.95K	-24.62K	-30.37K	-51.74K	-58.29K	-23.51K	-662.00	7.81K	26.24K	9.89K	-168.28K	165.15K	-282.58K	-15.63K	-31.77K	-32.83K	171.41K
Income Before Tax	-20.06M	-15.45M	-14.29M	-8.94M	-7.53M	-4.26M	-3.83M	-4.22M	-2.43M	-592.69K	284.91K	99.20K	-97.77K	-12.53K	-193.13K	-213.23K	203.55K	-101.83K	52.54K	-561.49K	69.98K	165.58K	-56.54K	-315.83K
Income Before Tax Ratio	-1,863.36%	-1,123.08%	-900.94%	-989.80%	-747.87%	-420.68%	-309.68%	-281.04%	-255.81%	-37.81%	16.83%	9.49%	-9.47%	-1.56%	-30.96%	-43.08%	27.10%	-18.78%	11.56%	-120.83%	17.74%	31.70%	-19.54%	-82.12%
Income Tax Expense	0.00	-171.00K	18.52K	-18.53K	141.75K	11.77K	0.00	28.60K	120.00K	33.67K	80.00K	25.00K	25.81K	25.00K	0.00	200.00K	-450.00K	168.28K	225.00K	282.58K	-225.00K	31.77K	90.17K	195.00K
Net Income	-20.06M	-15.28M	-14.31M	-8.92M	-7.67M	-4.26M	-3.83M	-4.22M	-2.55M	-592.69K	204.91K	74.20K	-97.77K	-37.53K	-193.13K	-413.23K	653.55K	-101.83K	-172.46K	-561.49K	294.98K	165.58K	-113.88K	-510.83K
Net Income Ratio	-1,863.36%	-1,110.65%	-902.10%	-987.75%	-761.94%	-420.68%	-309.68%	-281.04%	-268.44%	-37.81%	12.10%	7.10%	-9.47%	-4.68%	-30.96%	-83.49%	87.00%	-18.78%	-37.96%	-120.83%	74.77%	31.70%	-39.35%	-132.82%
EPS	-1.23	-1.81	-2.25	-5.58	-7.09	-5.20	-5.32	-6.67	-4.54	-1.17	1.00	1.00	-0.27	-0.11	-0.67	-1.76	3.60	-0.69	-1.44	-7.76	5.00	3.00	-2.59	-13.80
EPS Diluted	-1.23	-1.81	-2.25	-5.58	-7.09	-5.20	-5.32	-6.67	-4.54	-1.17	1.00	1.00	-0.27	-0.11	-0.67	-1.76	3.60	-0.69	-1.44	-7.76	5.00	3.00	-2.59	-13.80
Weighted Avg Shares Out	16.33M	8.44M	6.37M	1.60M	1.08M	817.57K	720.37K	633.54K	562.09K	505.43K	371.66K	366.80K	358.07K	337.11K	287.51K	235.33K	179.20K	148.15K	120.18K	72.32K	50.05K	47.91K	43.89K	37.02K
Weighted Avg Shares Out (Dil)	16.33M	8.44M	6.37M	1.60M	1.08M	817.57K	720.37K	633.54K	562.09K	505.43K	371.66K	366.80K	358.07K	337.11K	287.51K	235.33K	179.20K	148.15K	120.18K	72.32K	50.05K	47.91K	43.89K	37.02K

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 16, 2024businesswire.com

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the...

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

March 18, 2024businesswire.com

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease

March 14, 2024businesswire.com

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office

January 29, 2024businesswire.com

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

December 27, 2023businesswire.com

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) (“AMT”), a...

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

December 18, 2023businesswire.com

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, today announced a positive outcome from its recent Type...

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

November 28, 2023businesswire.com

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM:...

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

November 21, 2023businesswire.com

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, today announced its abstract has been accepted for platform...